Last reviewed 2026-04-23 · How we verify

Triptorelin Acetate PR 1-month

Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.

Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.

At a glance

Mechanism of action

Triptorelin binds to GnRH receptors in the pituitary gland, initially causing a surge in gonadotropin release followed by sustained suppression of LH and FSH through receptor desensitization. This results in profound suppression of testosterone in males and estrogen in females, making it useful for hormone-dependent conditions. The 1-month formulation provides sustained release of the peptide over approximately 30 days.

Approved indications

• Advanced prostate cancer
• Endometriosis
• Uterine fibroids
• Central precocious puberty

Common side effects

• Hot flashes
• Injection site reaction
• Headache
• Fatigue
• Decreased libido
• Erectile dysfunction
• Gynecomastia

Key clinical trials

• Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.